Curis (CRIS) Operating Income (2010 - 2026)
Curis' (CRIS) quarterly Operating Income came in at -$11.5 million in Q1 2026, down 13.41% YoY from -$13.3 million in Q1 2025, and down 158.71% on a QoQ basis from $19.6 million in Q4 2025.
Curis (CRIS) Operating Income (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Operating Income data on file, last reported at -$11.5 million in Q1 2026.
- Quarterly Operating Income fell 13.41% year-over-year to -$11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.1 million (up 83.25% YoY) and the FY2025 annual result came in at -$5.7 million, up 87.17% from the prior year.
- Operating Income declined to -$11.5 million in Q1 2026, from $19.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $19.6 million in Q4 2025 to a low of -$15.1 million in Q1 2022.
- A 5-year average of -$9.6 million and a median of -$11.6 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 71.97% — and 2025, when it jumped 318.13%.
- Tracing CRIS's Operating Income over 5 years: stood at -$10.2 million in 2022, then decreased by 19.36% to -$12.2 million in 2023, then gained by 26.27% to -$9.0 million in 2024, then jumped by 318.13% to $19.6 million in 2025, then plunged by 158.71% to -$11.5 million in 2026.
- The last three Operating Income figures came in at -$11.5 million (Q1 2026), $19.6 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -9.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.52 Mn |
| Dec 31, 2025 | 19.62 Mn |
| Sep 30, 2025 | -6.92 Mn |
| Jun 30, 2025 | -8.25 Mn |
| Mar 31, 2025 | -10.16 Mn |
| Dec 31, 2024 | -8.99 Mn |
| Sep 30, 2024 | -10.57 Mn |
| Jun 30, 2024 | -12.51 Mn |
| Mar 31, 2024 | -12.47 Mn |
| Dec 31, 2023 | -12.20 Mn |
| Sep 30, 2023 | -12.37 Mn |
| Jun 30, 2023 | -12.14 Mn |
| Mar 31, 2023 | -11.63 Mn |
| Dec 31, 2022 | -10.22 Mn |
| Sep 30, 2022 | -12.61 Mn |
| Jun 30, 2022 | -15.06 Mn |
| Mar 31, 2022 | -15.13 Mn |
| Dec 31, 2021 | -12.57 Mn |
| Sep 30, 2021 | -10.05 Mn |
| Jun 30, 2021 | -10.65 Mn |